Genenta Science, a clinical-stage biotechnology company pioneering the development of lentivirus-based first-in-class gene and cell therapies in cancer, is the first italian company to be list on NASDAQ.
The declaration of our President, Riccardo Palmisano
"An excellence of the Italian Biotech reaches an extraordinary milestone: Genenta Science is the first national company to be listed on Wall Street in the American tech list. An important confirmation of the value of our research and entrepreneurial skills, a further demonstration for the biotechnology sector of its will to look ahead and to work for fulfilling patients needs and shaping a better future. While overcoming still-standing limits within the national ecosystem, commitment and competence of our companies prove to be successful with arousing interest even beyond national borders, raising relevant financial resources. We are confident that our innovative and research-intensive entrepreneurial system will be able to draw further stimulus from this important result of one our associates. Our congratulations to Genenta, may this milestone be the first of a long series. Not only for Genenta but also for the whole Italian biotech".
Nasdaq closing bell ceremony
Dr Pierluigi Paracchi, Genenta Science CEO and Luigi Naldini Professor, Ph.D., M.D., Co-Founder & Executive Scientific Board Chairman, rings the Closing Bell.
About Genenta Science
Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
More info: www.genenta.com